Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study - PubMed

5 hours ago

GLP-1 receptor agonists (GLP-1 RAs) were studied for their impact on mental illness in people with depression and anxiety in Sweden.
The study included 95,490 individuals with depression or anxiety who used antidiabetic medications between 2009 and 2022.
Semaglutide and liraglutide were associated with a lower risk of worsening mental illness, while exenatide and dulaglutide showed no significant effect.
Semaglutide was particularly effective in reducing risks of worsening depression, anxiety, and substance use disorder.
Liraglutide was associated with a lower risk of worsening depression but not anxiety.
The study suggests semaglutide and liraglutide could be dually effective for diabetes/obesity and mental health conditions.
A within-individual design was used to minimize confounding factors.
The primary outcome was a composite of psychiatric hospitalization, sick leave for psychiatric reasons, self-harm hospitalization, or suicide.
The study was funded by the Sigrid Jusélius Foundation, Jane and Aatos Erkko Foundation, and the Finnish Ministry of Social Affairs and Health.
Randomized controlled trials are recommended to confirm these findings.

Hasty Briefsbeta